JBIO Jade Biosciences, Inc.

JBIO financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1798749 Exchange: Nasdaq SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Nov 13, 2026 Data checked: Nov 16, 2026
Showing 3 of 6 annual and 0 of 25 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
<br>Emerging growth company
Entity Type
Operating
Public Float
$289.40M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
DE
Fiscal Year End
December (1231)
Phone
(781) 312-3013
EIN
831377888
Headquarters
WALTHAM, MA, 02453
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: Aerovate Therapeutics, Inc. (2020–2025)

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
-
Net Income
$-163.12M
Total Assets
$486.39M
Total Equity
$455.50M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
-35.8%
Return on Assets
-33.5%
Current Ratio
16.03x

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

Jade Biosciences, Inc. recorded fiscal 2025 net loss of $127.41M. Diluted earnings per share were -$3.19, translating the period’s attributable earnings into the amount reported for each diluted share. A diluted share base of 31.36M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. The diluted share count was 887.5% higher than fiscal 2024, when diluted shares averaged 3.18M, adding context to the EPS comparison. Total assets stood at $349.78M, showing the scale of resources supporting revenue, earnings, liquidity, and financing.

Profitability

The company recorded an operating loss of $113.54M after the reported operating expense base. After all below-operating-line items, the company recorded a net loss of $127.41M for the fiscal year. EBITDA was negative $113.52M, showing a deficit before interest, taxes, depreciation, and amortization. The pretax result was a loss of $127.35M, establishing the deficit before tax effects. The reported income-tax provision was $58.00K, the amount recognized between pretax income and the final net-income result. The net loss equaled 38.3% of period-end equity, showing the deficit relative to book capital. The net loss equaled 36.4% of period-end assets, showing the deficit relative to the asset base. The net loss widened to $127.41M from $69.63M in fiscal 2024.

Liquidity and Capital Structure

The company held $349.78M of assets against $17.26M of liabilities and $332.52M of equity, revealing how the asset base was financed. The near-term balance sheet paired $348.82M of current assets with $16.54M of current liabilities at the reporting date. The current ratio was 21.09x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Reported cash and equivalents were $88.44M, separating immediately recognizable cash resources from the rest of the current-asset base. The cash balance equaled 534.7% of current liabilities, showing how much near-term coverage came from cash alone. The equity-to-assets relationship was 95.1%, placing book capital against the total resource base. Liabilities represented 4.9% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 25.3% of total assets, showing the liquid cash component within the company’s broader resource base. Compared with $72.80M in fiscal 2024, the current asset base moved 380.5% and finished higher. Compared with $69.39M in fiscal 2024, the current cash balance moved 27.5% and finished higher.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $94.69M, showing that operations absorbed cash during the period. The company spent $196.00K on capital expenditures while operations also absorbed cash, so both ongoing activity and investment drew on liquidity during the period. Operating cash flow and capital spending combined to leave a $94.89M cash deficit after capital spending. The cash deficit after capital spending represented 27.1% of the period-end asset base. The operating cash outflow widened to $94.69M from $71.20M in fiscal 2024.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for Jade Biosciences, Inc.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
OPERATING EXPENSES
R&D Expense $93.12M $53.19M $64.22M
SG&A Expense $20.42M $21.41M $17.19M
Operating Income $-113.54M $-74.60M $-81.41M
NON-OPERATING INCOME / EXPENSE
Other Income/Expense $-8.00K $-19.00K $-1.00K
Pretax Income $-127.35M $-69.57M $-75.47M
Income Tax $58.00K $55.00K $56.00K
Net Income $-127.41M $-69.63M $-75.52M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-3.19 $-21.96 $-25.83
Diluted Shares 31.36M 3.18M 2.93M
EBITDA $-113.52M $-74.31M $-81.31M
Depreciation & Amortization $26.00K $282.00K $96.00K
Balance Sheet
ASSETS
Cash & Equivalents $88.44M $69.39M $23.49M
Short-term Investments $247.72M $0 $98.95M
Other Current Assets $12.66M $268.00K $1.79M
Current Assets $348.82M $69.65M $124.23M
PP&E (Net) $170.00K $6.00K $288.00K
Other Noncurrent Assets $69.00K $3.15M $2.28M
Noncurrent Assets $965.00K $3.15M $3.19M
Total Assets $349.78M $72.80M $127.42M
LIABILITIES
Accounts Payable $2.15M $1.29M $2.40M
Other Current Liabilities - $319.00K $1.09M
Current Liabilities $16.54M $12.00M $17.64M
Other Noncurrent Liabilities - $70.00K $70.00K
Noncurrent Liabilities $724.00K $107.60M $325.00K
Total Liabilities $17.26M $119.60M $17.96M
EQUITY
Common Stock $5.00K $1.00K $3.00K
Additional Paid-in Capital $506.77M $309.38M $272.64M
Retained Earnings $-174.39M $-46.98M $-163.42M
Accumulated OCI $129.00K $0 $237.00K
Total Equity $332.52M $-46.80M $109.46M
Temporary Equity - $2.00K -
Total Liabilities & Equity $349.78M $72.80M $127.42M
SUPPLEMENTAL
Shares Outstanding 49.32M 3.67M 3.08M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-94.69M $-71.20M $-56.78M
Capital Expenditures $196.00K - $142.00K
Cash from Investing $-247.01M $56.03M $11.88M
Cash from Financing $360.77M $25.43M $46.00M
Free Cash Flow $-94.89M - $-56.92M
Beginning Cash (CFS) $69.39M $23.49M $22.40M
Net Change in Cash $19.07M $10.26M $1.09M
Effect of FX on Cash $-21.00K $0 $0
Calculated Ending Cash $88.44M $33.75M $23.49M
Cash per BS $88.44M $69.39M $23.49M
Cash scope difference (CFS − BS) - $-35.64M -
Cash per CFS $88.44M $33.75M $23.49M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

Is Jade Biosciences, Inc. profitable?

No. Jade Biosciences, Inc. reported $-163.12M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.